Figure 2

Change of CFT after treatment of ranibizumab and bevacizumab for myopic choroidal neovascularization. Graph shows changes of central foveal thickness (CFT) in optical coherence tomography from baseline to 12 months from treatment in both groups. There were significant decreases from baseline CFT after treatment in both groups. No statistical differences of CFT were observed at the same periods after treatment between two groups.